Disease: Blood coagulation disorders- inherited
- A novel heterozygous frameshift c.277del p.Thr93Leufs*21 mutation in SERPINC1 associated with type 1 antithrombin deficiency
- A treatment bridge for infants with hemophilia
- Abstracts of the 2024 International World Congress of the World Federation of Hemophilia 21-24 April 2024 Madrid, Spain
- Acquired bleeding disorders
- ACQUIRED HAEMOPHILIA A
- Acquired Hemophilia: A Rare Complication of Pediatric Idiopathic Multicentric Castleman Disease
- Adequate menstrual suppression in adolescents with inherited bleeding disorders often requires multiple treatment changes: Retrospective cohort study of a multidisciplinary clinic
- An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database
- Analysis of three Chinese pedigrees affected with Hereditary factor Ⅶ deficiency due to compound heterozygous variants of F7 gene
- Antithrombin deficiency caused by SERPINC1 gene mutation in white matter lesions: A case report
- Assessment of jaw bone mineral density, resorption rates, and oral health in patients with severe hemophilia: a case-control study
- Authors' Reply: "The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies"
- Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies
- Bernard-Soulier syndrome caused by two novel heterozygous <em>GP1BA</em> gene mutations: a case report and literature review
- Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond
- Challenges in ageing persons with haemophilia
- Clinical Analysis and Mental Health Survey of Hemophilia Carriers: a Cross-sectional Study
- Clinical and economic burden of immune tolerance induction in entire patients with hemophilia A: Insights from a real-world Korean setting
- Clinical and Molecular Characterization of Nine Novel Antithrombin Mutations
- Clinical characteristic and management of haemophilia patients in Malaysia: A single centre experience
- Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia
- Current and emerging gene therapies for haemophilia A and B
- Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients
- Defining success in haemophilia care - Are we doing it right?
- Dental management of people with complex or rare inherited bleeding disorders
- Diagnosis and treatment challenges in lower resource countries: State-of-the-art
- Diagnosis and treatment of von Willebrand disease in 2024 and beyond
- Effect of low fibrinogen level on in-hospital mortality and 6-month functional outcome of TBI patients, a single center experience
- Effect of statin intake on FVIII levels and bleeding outcomes in hypercholesterolemic patients with hemophilia A
- Eine Patientin mit gleichzeitiger Epidermolysis bullosa acquisita, erworbener Hämophilie und disseminierten Warzen: A patient with concomitant epidermolysis bullosa acquisita, acquired hemophilia and disseminated warts
- Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
- Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia
- Extracorporeal Membrane Oxygenation Combined With Interventional Thrombectomy for Treating High-Risk Pulmonary Embolism Caused by Protein C Deficiency:Report of One Case
- Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16<sup>+</sup> NK cell activation
- Fibrin glue in managing intractable gingival bleeding in patients with inherited bleeding disorders-a quasi-experimental pilot study
- Frequency of natural regulatory T cells specific for factor VIII in the peripheral blood of healthy donors
- Frequency, clinical, and laboratory findings of platelet secretion disorders in patients referred to the specialized coagulation laboratory of the Iranian Blood Transfusion Organization
- Haemophilia in the era of novel therapies: Where do inhibitors feature in the new landscape?
- Haemophilic arthropathy: Diagnosis, management, and aging patient considerations
- Heavy menstrual bleeding in women with inherited bleeding disorders in use of LNG-IUS: A systematic review and single-arm meta-analysis
- Hemophilia and hepatology, back to the future
- Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec
- Hepatitis after gene therapy, what are the possible causes?
- Heyde's syndrome: a challenging case of severe aortic stenosis and gastrointestinal bleeding
- How much prophylaxis is enough in haemophilia?
- Hypoprothrombinemia-lupus anticoagulant syndrome secondary to Sjogren's syndrome: A case report
- Identification of the Efficient Enhancer Elements in FVIII-Padua for Gene Therapy Study of Hemophilia A
- Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factor
- In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia
- Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study
- Incidence, clinical features, and risk factors of hemocoagulase-induced hypofibrinogenemia: A retrospective real-world study
- Laparoscopic Sleeve Gastrectomy with Staple-Line Oversewing in a Patient with Factor XI Deficiency: A Case Report
- Living with… hemophilia
- Lower-dose emicizumab prophylaxis: can less be more?
- Lupus anticoagulant hypoprothrombinemia syndrome with multiple and high-titer antiphospholipid antibodies strongly interfered with coagulation assays
- Methodological recommendations for surgical care in patients with hemophilia A receiving prophylactic therapy with emicizumab
- Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis
- Monitoring for liver cancer post-gene therapy-How much and how often?
- Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B
- Outcomes and outcome measures
- Paradox pain sensitivity using cuff pressure or algometer testing in patients with hemophilia
- Pediatric hemophilia patient: Successful desensitization for drug-induced fixed urticaria with prothrombin complex concentrate
- Perioperative management for fracture in a child with homozygous congenital protein C deficiency
- Phenotypic and genetic analysis of a Chinese pedigree affected with Hereditary antithrombin deficiency due to a novel variant of SERPINC1 gene
- Pulmonary thromboembolism associated with hereditary antithrombin III deficiency: A case report
- Rare bleeding disorders: Advances in management
- Rare Inherited Bleeding Disorders in The Middle East
- Recent advances in the replacement therapy for Hemophilia
- Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro
- Repair of type II paraesophageal hernia with Nissen fundoplication in a patient with von Willebrand disease and spondylolisthesis - a clinical case report
- Resolution of the Expert council on surgical care for hemophilia A patients on emicizumab use
- Riding the wave of change: Providing solid ground to support nursing with patient transitions to novel haemophilia therapies
- Safety and tolerability of OP-724 in patients with haemophilia and liver cirrhosis due to HIV/HCV coinfection: an investigator-initiated, open-label, non-randomised, single-centre, phase I study
- Severe case of postpartum-acquired haemophilia A after laparoscopic cholecystectomy
- Single centre experience of the use of emicizumab in previously untreated and minimally treated patients under 18 months of age
- Six-Year, Real-World Use of Prophylaxis with Recombinant Factor IX-Albumin Fusion Protein (rIX-FP) in Persons with Hemophilia B: A Single-Center Retrospective-Prospective Study
- Spectrum of WAS gene mutations in Vietnamese patients with Wiskott-Aldrich syndrome
- Spontaneous renal rupture caused by factor VII deficiency: A case report
- Stromal cell-derived factor 1 alpha (SDF-1alfa) and cartilage oligomeric matrix protein (COMP): Two potential signature biomarkers of radiological detectable hemophilic arthropathy
- Successful immunosuppressive therapy in female hemophilia A developing inhibitor after perioperative administration of factor VIII products
- Sustained good response to rituximab in acquired von Willebrand syndrome
- Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight
- The benefits of gene therapy in people with haemophilia
- The complex, confusing and poorly understood immune responses to AAV-mediated gene transfer in haemophilia-Is more or less immunosuppression required?
- The importance and evolution of bleeding disorder registries
- The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies
- The role of rheumatologist in the assessment of hemophilic arthropathy using head-us in patients with hemophilia
- The role of the specialist nurse in comprehensive care for bleeding disorders in Europe: An integrative review
- The role of viscoelastic hemostatic assays for postpartum hemorrhage management and bedside intrapartum care
- The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes
- The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A
- Tigecycline-associated hypofibrinogenemia: A single center, retrospective, controlled study
- Unresolved hemostasis issues in haemophilia
- Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders
- Using reference equations to standardise incremental shuttle walk test performance in children and young people with chronic conditions and facilitate the evaluation of exercise capacity and disease severity
- Validation for the function of protein C in mouse models
- Viral Vectors in Gene Replacement Therapy
- What is new…for factor XI inhibitors: DOAC 2.0?
- Which patients should be considered for gene therapy
- Women and girls with inherited bleeding disorders: Focus on haemophilia carriers and heavy menstrual bleeding